Table 2:
Key Baseline Characteristics of Patients Included in the GEMINI 1 study21
| Characteristic | Induction Phase | Maintenance Phase | |
|---|---|---|---|
| Vedolizumab every 8 weeks |
Vedolizumab every 4 weeks |
||
| No. of patients | 746 | 122 | 125 |
| Age, yrs (mean ± SD) | 40 ± 13 | 41 ± 13 | 39 ± 14 |
| Male sex | 58% | 57% | 54% |
| Disease duration (yrs) | 6.8 ± 6.2 | 6.2 ± 5 | 7.6 ± 7 |
| Mayo clinical score (mean ± SD) | 8.6 ± 1.8 | 8.4 ± 1.8 | 8.3 ± 1.7 |
| Received concomitant glucocorticoids or immunosuppressive agentsa | 72% | 75% | 74% |
| Received prior anti-TNF therapy | 48% | 41% | 42% |
anti-TNF = anti–tumor necrosis factor.
a
Immunosuppressive agents were azathioprine or 6-mercaptopurine.